Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Delanaye, Pierre ^a   Krzesinski, Jean Marie ^a   Warling, Xavier ^a   Moonen, Martial ^a   Smelten, Nicole ^b   Médart, Laurent ^a   Pottel, Hans ^c   Cavalier, Etienne ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Nephrology Dialysis Centre Hospitalier bois de l'Abbaye   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Matrix Gla protein; Vascular calcification; Vitamin K

Indexed keywords

ALBUMIN; ANTIVITAMIN K; C REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 23; MATRIX GLA PROTEIN; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; VITAMIN K GROUP; BIOLOGICAL MARKER; CALCIUM BINDING PROTEIN; SCLEROPROTEIN;

AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD VESSEL CALCIFICATION; BODY MASS; CARBOXYLATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PROTEIN PHOSPHORYLATION; SCORING SYSTEM; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BLOOD; MIDDLE AGED; PHOSPHORYLATION; PHYSIOLOGY; PREDICTIVE VALUE; RENAL REPLACEMENT THERAPY; VASCULAR CALCIFICATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CALCIUM-BINDING PROTEINS; COHORT STUDIES; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; VASCULAR CALCIFICATION; VITAMIN K;

EID: 84908291484     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-145     Document Type: Article

References (48)

1. Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Price PA, Urist MR, Otawara Y, Biochem Biophys Res Commun 1983 117 765 771 10.1016/0006-291X(83)91663-7 6607731
2. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G, Nature 1997 386 78 81 10.1038/386078a0 9052783
3. Matrix Gla protein metabolism in vascular smooth muscle and role in uremic vascular calcification. Lomashvili KA, Wang X, Wallin R, O'Neill WC, J Biol Chem 2011 286 28715 28722 10.1074/jbc.M111.251462 21705322
4. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. Zebboudj AF, Imura M, Bostrom K, J Biol Chem 2002 277 4388 4394 10.1074/jbc.M109683200 11741887
5. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. Murshed M, Schinke T, McKee MD, Karsenty G, J Cell Biol 2004 165 625 630 10.1083/jcb.200402046 15184399
6. Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. Schurgers LJ, Spronk HM, Skepper JN, Hackeng TM, Shanahan CM, Vermeer C, Weissberg PL, Proudfoot D, J Thromb Haemost 2007 5 2503 2511 10.1111/j.1538-7836.2007.02758.x 17848178
7. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. Schlieper G, Westenfeld R, Kruger T, Cranenburg EC, Magdeleyns EJ, Brandenburg VM, Djuric Z, Damjanovic T, Ketteler M, Vermeer C, Dimkovic N, Floege J, Schurgers LJ, J Am Soc Nephrol 2011 22 387 395 10.1681/ASN.2010040339 21289218
8. Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Cranenburg EC, Koos R, Schurgers LJ, Magdeleyns EJ, Schoonbrood TH, Landewe RB, Brandenburg VM, Bekers O, Vermeer C, Thromb Haemost 2010 104 811 822 10.1160/TH09-11-0786 20694284
9. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Schurgers LJ, Cranenburg EC, Vermeer C, Thromb Haemost 2008 100 593 603 18841280
10. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Westenfeld R, Krueger T, Schlieper G, Cranenburg EC, Magdeleyns EJ, Heidenreich S, Holzmann S, Vermeer C, Jahnen-Dechent W, Ketteler M, Floege J, Schurgers LJ, Am J Kidney Dis 2012 59 186 195 10.1053/j.ajkd.2011.10.041 22169620
11. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC, Am J Kidney Dis 1996 27 394 401 10.1016/S0272-6386(96)90363-7 8604709
12. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB, N Engl J Med 2000 342 1478 1483 10.1056/NEJM200005183422003 10816185
13. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C, Nephrol Dial Transplant 2009 24 948 955 18852190
14. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F, Circulation 2002 106 100 105 10.1161/01.CIR.0000020222.63035.C0 12093777
15. A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients. Adragao T, Pires A, Birne R, Curto JD, Lucas C, Goncalves M, Negrao AP, Nephrol Dial Transplant 2009 24 997 1002 18952701
16. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H, Nephrol Dial Transplant 2003 18 1731 1740 10.1093/ndt/gfg414 12937218
17. Vascular access calcification predicts mortality in hemodialysis patients. Schlieper G, Kruger T, Djuric Z, Damjanovic T, Markovic N, Schurgers LJ, Brandenburg VM, Westenfeld R, Dimkovic S, Ketteler M, Grootendorst DC, Dekker FW, Floege J, Dimkovic N, Kidney Int 2008 74 1582 1587 10.1038/ki.2008.458 18800030
18. Vitamin K: key vitamin in controlling vascular calcification in chronic kidney disease. Schurgers LJ, Kidney Int 2013 83 782 784 10.1038/ki.2013.26 23633049
19. Vitamins K and D status in stages 3-5 chronic kidney disease. Holden RM, Morton AR, Garland JS, Pavlov A, Day AG, Booth SL, Clin J Am Soc Nephrol 2010 5 590 597 10.2215/CJN.06420909 20167683
20. Subclinical vitamin K deficiency in hemodialysis patients. Pilkey RM, Morton AR, Boffa MB, Noordhof C, Day AG, Su Y, Miller LM, Koschinsky ML, Booth SL, Am J Kidney Dis 2007 49 432 439 10.1053/j.ajkd.2006.11.041 17336705
21. Vitamin K intake and status are low in hemodialysis patients. Cranenburg EC, Schurgers LJ, Uiterwijk HH, Beulens JW, Dalmeijer GW, Westerhuis R, Magdeleyns EJ, Herfs M, Vermeer C, Laverman GD, Kidney Int 2012 82 605 610 10.1038/ki.2012.191 22648294
22. Vitamin K, vertebral fractures, vascular calcifications, and mortality: VItamin K Italian (VIKI) dialysis study. Fusaro M, Noale M, Viola V, Galli F, Tripepi G, Vajente N, Plebani M, Zaninotto M, Guglielmi G, Miotto D, Dalle CL, D'Angelo A, Naso A, Grimaldi C, Miozzo D, Giannini S, Gallieni M, J Bone Miner Res 2012 27 2271 2278 10.1002/jbmr.1677 22692665
23. Vitamin k intake and plasma desphospho-uncarboxylated matrix Gla-protein levels in kidney transplant recipients. Boxma PY, van den Berg E, Geleijnse JM, Laverman GD, Schurgers LJ, Vermeer C, Kema IP, Muskiet FA, Navis G, Bakker SJ, de Borst MH, PLoS One 2012 7 47991 10.1371/journal.pone.0047991 23118917
24. Vitamin K status in chronic kidney disease: a report of a study and a mini-review. Voong K, Harrington D, Goldsmith D, Int Urol Nephrol 2013 45 1339 1344 10.1007/s11255-012-0367-x 23296791
25. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, Vermeer C, Choukroun G, Massy ZA, Clin J Am Soc Nephrol 2010 5 568 575 10.2215/CJN.07081009 20133489
26. Circulating uncarboxylated matrix gla protein is associated with vitamin K nutritional status, but not coronary artery calcium, in older adults. Shea MK, O'Donnell CJ, Vermeer C, Magdeleyns EJ, Crosier MD, Gundberg CM, Ordovas JM, Kritchevsky SB, Booth SL, J Nutr 2011 141 1529 1534 10.3945/jn.111.139634 21628633
27. Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Caluwe R, Vandecasteele S, Van VB, Vermeer C, De Vriese AS, Nephrol Dial Transplant 2014 29 1385 1390 10.1093/ndt/gft464 24285428
28. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Shea MK, O'Donnell CJ, Hoffmann U, Dallal GE, Dawson-Hughes B, Ordovas JM, Price PA, Williamson MK, Booth SL, Am J Clin Nutr 2009 89 1799 1807 10.3945/ajcn.2008.27338 19386744
29. Circulating matrix Gla protein is associated with coronary artery calcification and vitamin K status in healthy women. Dalmeijer GW, van der Schouw YT, Vermeer C, Magdeleyns EJ, Schurgers LJ, Beulens JW, J Nutr Biochem 2013 24 624 628 10.1016/j.jnutbio.2012.02.012 22819559
30. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, Kidney Int Suppl 2009 113 1 130 19644521
31. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW, Atherosclerosis 1997 132 245 250 10.1016/S0021-9150(97)00106-8 9242971
32. Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis. Ueland T, Gullestad L, Dahl CP, Aukrust P, Aakhus S, Solberg OG, Vermeer C, Schurgers LJ, J Intern Med 2010 268 483 492 10.1111/j.1365-2796.2010.02264.x 20804515
33. Renal handling of matrix Gla-protein in humans with moderate to severe hypertension. Rennenberg RJ, Schurgers LJ, Vermeer C, Scholte JB, Houben AJ, de Leeuw PW, Kroon AA, Hypertens Res 2008 31 1745 1751 10.1291/hypres.31.1745 18971553
34. Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. Krueger T, Schlieper G, Schurgers L, Cornelis T, Cozzolino M, Jacobi J, Jadoul M, Ketteler M, Rump LC, Stenvinkel P, Westenfeld R, Wiecek A, Reinartz S, Hilgers RD, Floege J, Nephrol Dial Transplant 2014 29 1633 1638 10.1093/ndt/gft459 24285427
35. Coronary calcifications in end-stage renal disease patients: a new link between osteoprotegerin, diabetes and body mass index? Cianciolo G, La Manna G, Donati G, Persici E, Dormi A, Cappuccilli ML, Corsini S, Fattori R, Russo V, Nastasi V, Coli L, Wratten M, Stefoni S, Blood Purif 2010 29 13 22 10.1159/000245042 19816015
36. Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Cranenburg EC, Brandenburg VM, Vermeer C, Stenger M, Muhlenbruch G, Mahnken AH, Gladziwa U, Ketteler M, Schurgers LJ, Thromb Haemost 2009 101 359 366 19190822
37. Undercarboxylated matrix GLA protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index. Hermans MM, Vermeer C, Kooman JP, Brandenburg V, Ketteler M, Gladziwa U, Rensma PL, Leunissen KM, Schurgers LJ, Blood Purif 2007 25 395 401 10.1159/000108629 17890861
38. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Jono S, Ikari Y, Vermeer C, Dissel P, Hasegawa K, Shioi A, Taniwaki H, Kizu A, Nishizawa Y, Saito S, Thromb Haemost 2004 91 790 794 15045141
39. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. McCabe KM, Booth SL, Fu X, Shobeiri N, Pang JJ, Adams MA, Holden RM, Kidney Int 2013 83 835 844 10.1038/ki.2012.477 23344475
40. Calciphylaxis in CKD and beyond. Brandenburg VM, Kramann R, Specht P, Ketteler M, Nephrol Dial Transplant 2012 27 1314 1318 10.1093/ndt/gfs015 22344774
41. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. Chan KE, Lazarus JM, Thadhani R, Hakim RM, J Am Soc Nephrol 2009 20 2223 2233 10.1681/ASN.2009030319 19713308
42. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Koos R, Mahnken AH, Muhlenbruch G, Brandenburg V, Pflueger B, Wildberger JE, Kuhl HP, Am J Cardiol 2005 96 747 749 10.1016/j.amjcard.2005.05.014 16169351
43. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Price PA, Faus SA, Williamson MK, Arterioscler Thromb Vasc Biol 1998 18 1400 1407 10.1161/01.ATV.18.9.1400 9743228
44. Association of warfarin use with valvular and vascular calcification: a review. Palaniswamy C, Sekhri A, Aronow WS, Kalra A, Peterson SJ, Clin Cardiol 2011 34 74 81 10.1002/clc.20865 21298649
45. Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. Schurgers LJ, Joosen IA, Laufer EM, Chatrou ML, Herfs M, Winkens MH, Westenfeld R, Veulemans V, Krueger T, Shanahan CM, Jahnen-Dechent W, Biessen E, Narula J, Vermeer C, Hofstra L, Reutelingsperger CP, PLoS One 2012 7 43229 10.1371/journal.pone.0043229 22952653
46. Warfarin and aortic valve calcification in hemodialysis patients. Holden RM, Sanfilippo AS, Hopman WM, Zimmerman D, Garland JS, Morton AR, J Nephrol 2007 20 417 422 17879207
47. Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification? Krueger T, Westenfeld R, Ketteler M, Schurgers LJ, Floege J, Kidney Int 2009 76 18 22 10.1038/ki.2009.126 19387474
48. Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. Spronk HM, Soute BA, Schurgers LJ, Thijssen HH, De Mey JG, Vermeer C, J Vasc Res 2003 40 531 537 10.1159/000075344 14654717